Join our daily newsletter At The Bell to receive exclusive market insights
- Tim Poole will step down as the Chair of ASX 200-listed McMillan Shakespeare (MMS) following the company’s AGM on October 20
- He will be succeeded by Helen Kurincic, who joined McMillan Shakespeare’s Board in September 2018
- Tim will continue with the company as a Non-Executive Director until October next year
- The transition comes just a day after the news of a $2 million settlement related to the National Warranty Company class action
- McMillan Shakespeare (MMS) closed 0.34 per cent in the red for $8.77 each
Tim Poole will step down as the Chair of ASX 200-listed McMillan Shakespeare (MMS) following the company’s AGM on October 20.
He will be succeeded by Helen Kurincic, who joined the company’s Board in September 2018.
While not details were given regarding the purpose of the reshuffle, Tim will remain with McMillan Shakespeare as a Non-Executive Director until October next year.
Commenting on the transition, Tim noted that Helen has an extensive understanding of the business, as well as the opportunities that lie ahead.
“She is an outstanding director and I look forward to continuing to work closely with Helen during the next year,” he added.
In addition to her position with McMillan Shakespeare, Helen is currently the Non-Executive Chair of Integral Diagnostics, and is a non-executive director of Estia Health, HBF Health and Victorian Clinical Genetics Services.
Prior to her directorial roles, Helen acted as Chief Operating Officer of Genesis Care where – since it was founded – she was integral in the development of what is now Australia’s largest radiation oncology and cardiology business.
Helen said she is honoured to be taking over as the McMillan Shakespeare’s next Chair.
“We have a range of opportunities in front of us to grow and improve our businesses. I am looking forward to working with the Board and management team to deliver on these opportunities and maximise returns to shareholders,” she added.
The appointed comes just a day after McMillan Shakespeare announced a $2 million settlement of the National Warranty Company class action.
The motion was filed in August 2018, and sought refunds for void warranties that were issued from July 2013 to May 2015.
McMillan Shakespeare (MMS) closed 0.34 per cent in the red for $8.77 each.
